A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

NCT06972459 · tracked via the Priya Life Science Japan tracker

Sponsor

Eli Lilly and Company

Phase

Phase 3

Started

2025-05-15

Last updated

2026-07-29

Condition(s) studied

ObesityOverweight

Investigational drug(s) / intervention(s)

Orforglipron →Placebo

Orforglipron: Administered orally

Placebo: Administered orally

Study summary

The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health condition (excluding type 2 diabetes). This trial is part of the master protocol study J2A-MC-GZPO (NCT06993792).

Participation in the study will last about 18 months.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Have body mass index (BMI) ≥30 kilograms per square meter (kg/m2) or BMI ≥25.0 kg/m2 and at least 1 of the following weight-related comorbidities at screening: * hypertension * dyslipidemia * obstructive sleep apnea, or * cardiovascular disease * Have a history of at least one unsuccessful dietary effort to lose body weight Exclusion Criteria: * Have type 1 diabetes, type 2 diabetes, or any other types of diabetes * Have an unstable body weight within 90 days prior to screening * Have New York Heart Association functional classification IV congestive heart failure or an acute cardiovascular condition within 90 days prior to screening * Have acute or chronic hepatitis or pancreatitis * Are taking other medications or alternative remedies to manage weight loss

Primary outcome measure(s)

Percent Change from Baseline in Body Weight — Baseline, Week 72

Trial sites (80)

Facility	City	Region
Clinical Research Institute of Arizona (CRI) - Sun City West	Sun City West	Arizona
Novak Clinical Research - Tucson - North La Cholla Boulevard	Tucson	Arizona
Norcal Endocrinology & Internal Medicine	San Ramon	California
Southern California Clinical Research	Santa Ana	California
Care Access - Thousand Oaks	Thousand Oaks	California
Accel Research Sites - DeLand Clinical Research Unit	DeLand	Florida
Innovation Medical Research Center - Fort Lauderdale	Fort Lauderdale	Florida
Indago Research & Health Center, Inc	Hialeah	Florida
Encore Medical Research	Hollywood	Florida
West Orange Endocrinology P.A.	Ocoee	Florida
Care Access - Tampa	Tampa	Florida
Conquest Research	Winter Park	Florida
Accel Research Sites - NeuroStudies Clinical Research Unit	Decatur	Georgia
Care Access - Decatur	Decatur	Georgia
Javara - Privia Medical Group Georgia - Savannah	Savannah	Georgia
North Georgia Clinical Research	Woodstock	Georgia
Solaris Clinical Research	Meridian	Idaho
Care Access - New Iberia	New Iberia	Louisiana
Endocrine and Metabolic Consultants	Rockville	Maryland
Javara - Privia Medical Group - Silver Spring	Silver Spring	Maryland
Great Lakes Research Group, Inc.	Bay City	Michigan
Boeson Research MSO	Missoula	Montana
Javara - Nevada Health Centers - Carson City	Carson City	Nevada
The Machuca Foundation	Las Vegas	Nevada
University of North Carolina Medical Center	Chapel Hill	North Carolina
Javara - Tryon Medical Partners	Charlotte	North Carolina
Care Access - Fayetteville	Fayetteville	North Carolina
The Corvallis Clinic, P.C.	Corvallis	Oregon
Clinical Research of Philadelphia	Philadelphia	Pennsylvania
Frontier Clinical Research, LLC	Smithfield	Pennsylvania
Velocity Clinical Research, Dallas	Dallas	Texas
Biopharma Informatic, LLC	Houston	Texas
Activian Clinical Research	Kingwood	Texas
Texas Valley Clinical Research (TVCR) - Mission	Mission	Texas
Consano Clinical Research, LLC	Shavano Park	Texas
CARE - Centro de Alergia y Enfermedades Respiratorias	Buenos Aires	Argentina
CIPREC	Buenos Aires	Argentina
Centro Médico Viamonte	Buenos Aires	Argentina
Instituto Centenario	CABA	Argentina
Instituto Médico Catamarca IMEC	Rosario	Argentina

+ 40 more sites — see the full list on the official registry below.

More Eli Lilly and Company trials in Japan

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer Active, not recruiting

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 Recruiting

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) Active, not recruiting

A Study of LY3200882 in Participants With Solid Tumors Active, not recruiting

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C) Recruiting

Other trials for the same condition

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity Recruiting

Bariatric Surgery Combined With GLP-1 Receptor Agonists Study Recruiting

GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity Recruiting

Bariatric Surgery Combined With GLP-1RA: A Multicenter Study. Recruiting

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06972459 on ClinicalTrials.gov ↗ ← All trials in Japan